We are live on
!
Find out more
NLG
New Legacy Group Portfolio holdings
AUM
$36.6M
1-Year Est. Return
36.77%
This Fund
S&P 500
This Quarter
Est. Return
+3.18%
1 Year Est. Return
+36.77%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$38.8M
AUM Growth
-$10.5M
(-21%)
Cap. Flow
-$14.3M
Cap. Flow
% of AUM
-36.84%
Top 10 Holdings %
Top 10 Hldgs %
80.15%
Holding
28
New
–
Increased
–
Reduced
3
Closed
1
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$13.9M |
| 2 |
Apple
AAPL
|
+$188K |
| 3 |
PHAS
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
|
+$144K |
| 4 |
iShares Intermediate Government/Credit Bond ETF
GVI
|
+$63K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 23.48% |
| 2 | Communication Services | 10.69% |
| 3 | Technology | 7.21% |
| 4 | Healthcare | 0% |
Similar funds
BEVI
BGDR
ZAM
HCM
MAM
QI
AC
SAM
New Legacy Group's Q3 2022 Portfolio in Review
As of Q3 2022, New Legacy Group held 28 positions worth $38.8M, down 21% from $49.3M the previous quarter. Its ten largest holdings account for 80% of the portfolio.
New Legacy Group withdrew a net $14.3M in Q3 2022, closing 1 position and reducing 3 holdings. Its most notable exit was PhaseBio Pharmaceuticals, Inc. Common Stock, an estimated $144K position sold in full.
By sector, the portfolio is most concentrated in Consumer Discretionary at 23% of assets, down from 36% a quarter earlier, followed by Communication Services and Technology.
- New Legacy Group's biggest Q3 2022 reduction was Rivian, cutting an estimated $13.9M.
- New Legacy Group fully exited PhaseBio Pharmaceuticals, Inc. Common Stock in Q3 2022, selling an estimated $144K.
- New Legacy Group's ten largest holdings make up 80% of its $38.8M portfolio in Q3 2022.
- New Legacy Group opened 0 new positions and closed 1 in Q3 2022.
- New Legacy Group's portfolio value fell 21% quarter-over-quarter to $38.8M.
Based on New Legacy Group's 13F filing for Q3 2022, filed 14 Nov 2022.